PRFX Share Price | PainReform Ltd. Stock Analysis & Recommendation

Q: How big is PainReform Ltd.?

Market Cap: As of Jun 18, PainReform Ltd. has a market capitalization of 3.46 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, PainReform Ltd. reported net sales of 0.00 million and a consolidated net profit of -17.67 million.Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds stand at 1.82 million, while total assets are reported at 4.53 million.

Q: What does PainReform Ltd. do?

Overview:PainReform Ltd. is an Israel-based pharmaceutical company focused on the reformulation of established pain therapeutics, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:- Most recent Net Profit: -7 Million (Quarterly Results - Jun 2024)- Market-cap: USD 3.46 Million (Micro Cap)Key Metrics:- Debt Equity: 1.34- Return on Equity: -961.02%- Price to Book: 1.90Contact Details:- Address: 4 Bruria St., TEL AVIV-YAFO None: 6745442- Tel: 972 9 9601901- Fax: 972 9 9542266- Website: http://www.painreform.com

Q: Is PainReform Ltd. technically bullish or bearish?

As of 5 September 2025, the technical trend for PainReform Ltd. has changed from sideways to mildly bearish. The current stance is bearish, primarily driven by the daily moving averages indicating a bearish trend, while the Bollinger Bands show a mildly bearish to bearish outlook on the weekly and monthly time frames. Although the MACD and KST are mildly bullish on the weekly and monthly charts, they are overshadowed by the bearish signals from the moving averages and Bollinger Bands. In terms of performance, PainReform has significantly underperformed compared to the S&P 500, with a year-to-date return of -57.68% versus the S&P 500's 12.22%, and a one-year return of -57.23% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

63.47 k

Shareholding (Jun 2025)

FII

0.14%

Held by 3 FIIs

DII

99.86%

Held by 0 DIIs

Promoter

0.00%

How big is PainReform Ltd.?

22-Jun-2025

As of Jun 18, PainReform Ltd. has a market capitalization of 3.46 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a consolidated net profit of -17.67 million over the latest four quarters.

View full answer

What does PainReform Ltd. do?

22-Jun-2025

PainReform Ltd. is an Israeli pharmaceutical company specializing in the reformulation of existing pain medications, classified as a micro-cap with a market cap of USD 3.46 million and a recent net profit of -7 million.

View full answer

Is PainReform Ltd. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, PainReform Ltd. is in a mildly bearish trend, with significant underperformance at -57.68% year-to-date compared to the S&P 500's 12.22%, driven by bearish signals from moving averages and Bollinger Bands despite some mildly bullish indicators.

View full answer

Compare PainReform Ltd. with Similar Stocks

TRACON Pharmaceuticals, Inc.Windtree Therapeutics, Inc.Silo Pharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.41

Return on Equity

-207.62%

Price to Book

0.23

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2024)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-79.54%

6 Months

-79.74%

1 Year

-96.03%

2 Years

-99.5%

3 Years

-99.76%

4 Years

-99.91%

5 Years

0.0%

PainReform Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-266.98%

EBIT to Interest (avg)

-13.80

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.32

Sales to Capital Employed (avg)

Tax Ratio

0.05%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

4.03%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.27

EV to EBIT

0.00

EV to EBITDA

EV to Capital Employed

0.03

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

742.13%

ROE (Latest)

-961.02%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (0.14%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is -231.82% vs -22.22% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.30",
          "val2": "-2.20",
          "chgp": "-231.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.30",
          "val2": "-2.20",
          "chgp": "-231.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -56.99% vs -5.68% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.70",
          "val2": "-9.60",
          "chgp": "-53.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.60",
          "val2": "-9.30",
          "chgp": "-56.99%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY

Jun'24

Jun'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-7.30

-2.20

-231.82%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.30

-2.20

-231.82%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2024 is 0.00% vs 0.00% in Jun 2023

Consolidated Net Profit

YoY Growth in quarter ended Jun 2024 is -231.82% vs -22.22% in Jun 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.70

-9.60

-53.12%

Interest

0.00

0.40

-100.00%

Exceptional Items

0.00

0.20

-100.00%

Consolidate Net Profit

-14.60

-9.30

-56.99%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -56.99% vs -5.68% in Dec 2023

All Annual Results

Company CV

About PainReform Ltd.

PainReform Ltd.

Pharmaceuticals & Biotechnology

PAINREFORM LTD is a Israel-based pharmaceutical Company. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.

Company Coordinates

Company Details

4 Bruria St. , TEL AVIV-YAFO None : 6745442

Tel: 972 9 9601901

http://www.painreform.com

Registrar Details

PainReform Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

How big is PainReform Ltd.?

Watch in Real-Time

What does PainReform Ltd. do?

Is PainReform Ltd. technically bullish or bearish?

Compare PainReform Ltd. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About PainReform Ltd.

Company Coordinates